



## NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2007 (Rs. In Lacs)**

PARTICULARS	Three Month ended		Year ended	
	31/03/2007 ( Unaudited )	31/03/2006 ( Unaudited )	31/03/2007 ( Unaudited )	31/03/2006 ( Audited )
<b>Sales / Operational Income</b>	<b>16,812.98</b>	<b>7,641.82</b>	<b>46,124.95</b>	<b>28,725.08</b>
Other Income	266.17	1,230.77	1,722.89	2,321.56
<b>Total Expenditure</b>	<b>14,046.56</b>	<b>7,171.64</b>	<b>38,964.12</b>	<b>26,225.83</b>
a. (Increase)/decrease in stock in trade	1,168.09	57.88	(1,851.02)	160.27
b. Consumption of Raw Material	10,482.35	5,415.61	32,636.25	20,092.48
c. Staff Cost	439.43	210.39	1,067.45	637.99
d. Other Expenditure	1,956.70	1,487.77	7,111.44	5,335.10
Interest	834.45	112.27	2,226.90	811.63
Depreciation	332.17	264.75	955.71	735.74
<b>Profit before tax</b>	<b>1,865.97</b>	<b>1,323.94</b>	<b>5,701.11</b>	<b>3,273.44</b>
Provision for Current Tax & FBT	207.84	162.02	691.63	473.13
<b>Net Profit before Deferred tax</b>	<b>1,658.13</b>	<b>1,161.92</b>	<b>5,009.48</b>	<b>2,800.31</b>
Provision for Deferred tax	-	-	402.15	245.30
Tax & Exp. Relating to Earlier years	-	-	-	48.61
<b>Net Profit</b>	<b>1,658.13</b>	<b>1,161.92</b>	<b>4,607.33</b>	<b>2,506.41</b>
Paid up Equity Share Capital	1,488.67	1,488.67	1,488.67	1,488.67
Reserves excluding revaluation reserves	20,441.06	15,833.72	20,441.06	15,833.72
EPS ( Rs.)	11.14	7.81	30.95	18.21
Diluted EPS ( Rs.)	7.98	-	22.17	-
Non Promoters Holding				
No. of Shares	5072503	5072503	5072503	5072503
Percentage of total holding	34.07	34.07	34.07	34.07

**Notes:**

1. The above financial results were reviewed by Audit Committee on 27.04.2007 and taken on record by the Board in its meeting held on 28.04.2007.
2. The above financial results are on stand alone basis.
3. The company is exclusively in the pharmaceutical business segment.
4. The Audit Committee in its Meeting held on 27.04.2007 has recommended to the Board of Directors for a Final Dividend @20% to the Members, which the Board has accepted to consider at the time of adoption of audited financial statements for the year ended 31.03.2007
5. The manufacturing facilities for Cephalosporin Formulation Unit and Empty Hard Geletine Capsule Unit, both at Baddi, Himachal Pradesh stands completed during the month of March, 2007 and both the units have commenced commercial production w.e.f. April, 2007.
6. The total sales for the year ended 31.03.2007 includes 41% export sales.
7. Status of Complaints:
  - a) Pending as on 01.01.2007 - Nil
  - b) Received During the Quarter - 2
  - c) Disposed Off During the Quarter - 2
  - d) Pending as on 31.03.2007 - Nil

**Dated: 28.04.2007**

**Place: Chandigarh**

**By Order of the Board of Directors  
of Nectar Lifesciences Limited  
Sd/-**

**Sanjiv Goyal  
Managing Director**